Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $35.00 | Outperform | Wedbush |
| 2/4/2025 | $19.00 | Outperform | Wolfe Research |
| 12/16/2024 | $30.00 | Buy | H.C. Wainwright |
| 11/5/2024 | $34.00 | Buy | Rodman & Renshaw |
| 10/8/2024 | $45.00 | Buy | Guggenheim |
| 10/8/2024 | $40.00 | Overweight | Morgan Stanley |
| 10/8/2024 | $35.00 | Buy | Jefferies |
| 10/8/2024 | $27.00 | Buy | Citigroup |
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September: Citi's 2025 Biopharma Back to School Conference on Tuesday, September 2, 2025, at 1:00 p.m. ETCantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 8:35 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 7:45 a.m. ET Live webcasts and archived
4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)
8-K - Zenas BioPharma, Inc. (0001953926) (Filer)
S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)
Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00
Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00
H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)